Top Suppliers:I want be here
  • BioBioPha
  • China
  • Product Name: Deslanoside
  • Price: ￥Inquiry/5mg
  • Purity: 98.0%
  • Stocking Period: 10 Day
  • Contact: Xueping-Zheng
Related CAS#:
17598-65-1 103016-02-0
1158522-08-7 940364-43-2
134104-43-1 2137798-62-8
131615-57-1 1865048-57-2
6906-52-1 930439-75-1
1018584-77-4 1375289-11-4

17598-65-1

17598-65-1 structure
17598-65-1 structure
  • Name: Deslanoside
  • Chemical Name: deslanoside
  • CAS Number: 17598-65-1
  • Molecular Formula: C47H74O19
  • Molecular Weight: 943.079
  • Catalog: API Circulatory system medication Anti-congestive heart failure medicine
  • Create Date: 2018-03-03 08:00:00
  • Modify Date: 2024-01-03 10:44:19
  • Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations [1][2][3].
Name deslanoside
Synonyms Card-20(22)-enolide, 3-((O-β-D-glucopyranosyl-(1->4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3β,5β,12β)-
Deacetyllanatoside C
Desacetyllanatoside C
Deslanatoside C
Deslanoside
Deacetyllanatoside C,Desacetyllanatoside C
Cedilanide
(3β,5β,12β)-3-{[β-D-Glucopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide
deacetyl-lanatoside
4-18-00-02455 (Beilstein Handbook Reference)
Desacetyldigilanide C
Descetyldigilanide C
DESLANOSIDUM
4-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-Dihydroxy-3-{[(2R,4S,5S,6R)-4-hydroxy-5-{[(2S,4S,5S,6R)-4-hydroxy-5-{[(2S,4S,5S,6R)-4-hydroxy-6-methyl-5-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}tetrahydro-2H-pyran-2-yl]oxy}-6-methyltetrahydro-2H-pyran-2-yl]oxy}-6-methyltetrahydro-2H-pyran-2-yl]oxy}-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2(5H)-furanone
Desaci
Desace
MFCD00135818
deacetyl-lanatoside C
Card-20(22)-enolide, 3-[[O-β-D-glucopyranosyl-(1->4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy]-12,14-d ihydroxy-, (3β,5β,12β)-
Deslanatoside
Purpurea Glycoside C
Desacetyllanatosid C
card-20(22)-enolide, 3-[[O-β-D-glucopyranosyl-(1->4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy]-12,14-dihydroxy-, (3β,5β,12β)-
glucodigoxin
Deslanosidum C
(3β,5β,12β)-3-{[β-D-Glucopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy}-12,14-dihydro
 xycard-20(22)-enolide
4-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-Dihydroxy-3-{[(2R,4S,5S,6R)-4-hydroxy-5-{[(2S,4S,5S,6R)-4-hydroxy-5-{[(2S,4S,5S,6R)-4-hydroxy-6-méthyl-5-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxyméthyl)tétrahydro-2H-pyran-2-yl]oxy}tétrahydro-2H-pyran-2-yl]oxy}-6-méthyltétrahydro-2H-pyran-2-yl]oxy}-6-méthyltétrahydro-2H-pyran-2-yl]oxy}-10,13-diméthylhexadécahydro-1H-cyclopenta[a]phénanthrén-17-yl]-2(5H)-furanone
cedilanidd
sediranido
EINECS 241-568-1
de-O-acetyl-lanatoside C
4-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-Dihydroxy-3-{[(2R,4S,5S,6R)-4-hydroxy-5-{[(2S,4S,5S,6R)-4-hydroxy-5-{[(2S,4S,5S,6R)-4-hydroxy-6-methyl-5-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}tetrahydro-2H-pyran-2-yl]oxy}-6-methyltetrahydro-2H-pyran-2-yl]oxy}-6-methyltetrahydro-2H-pyran-2-yl]oxy}-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2(5H)-furanon
Description Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations [1][2][3].
Related Catalog
In Vitro Deslanoside (Desacetyllanatoside C) is a metabolite of Lanatoside C[4]. Deslanoside increases forearm blood flow and cardiac index and decreased heart rate concomitant with a marked decrease in skeletal muscle sympathetic nerve activity measured as an indicator of centrally mediated sympathetic nervous system activity[1].
References

[1]. Hauptman PJ, et al. Digitalis. Circulation. 1999 Mar 9;99(9):1265-70.

[2]. Wang L, et al. Ontology-based systematical representation and drug class effect analysis of package insert-reported adverse events associated with cardiovascular drugs used in China. Sci Rep. 2017 Oct 23;7(1):13819.

[3]. Deslanoside.

[4]. Klys M, et al. Determination of deslanoside in antemortem and postmortem specimens. Unusual case report. Forensic Sci Int. 1990 Apr;45(3):231-8.

[5]. Klys M, et al. Determination of deslanoside in antemortem and postmortem specimens. Unusual case report. Forensic Sci Int. 1990 Apr;45(3):231-8.
Density 1.4±0.1 g/cm3
Melting Point 220-235ºC
Molecular Formula C47H74O19
Molecular Weight 943.079
Exact Mass 942.482422
PSA 282.21000
LogP -1.40
Index of Refraction 1.620
Storage condition 2-8°C

CHEMICAL IDENTIFICATION

RTECS NUMBER :
OE2100500
CHEMICAL NAME :
Lanatoside C, deacetyl-
CAS REGISTRY NUMBER :
17598-65-1
BEILSTEIN REFERENCE NO. :
0078187
LAST UPDATED :
199612
DATA ITEMS CITED :
5
MOLECULAR FORMULA :
C47-H74-O19
MOLECULAR WEIGHT :
943.21

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
10360 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,489,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
8100 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,489,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - cat
DOSE/DURATION :
230 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
85ELDJ "Die Herzwirksamen Glykoside," Baumgarten, G., and W. Forster, Leipzig, Ger. Dem. Rep., VEB Georg Thieme, 1963 Volume(issue)/page/year: -,190,1963 *** REVIEWS *** TOXICOLOGY REVIEW 85ELDJ "Die Herzwirksamen Glykoside," Baumgarten, G., and W. Forster, Leipzig, Ger. Dem. Rep., VEB Georg Thieme, 1963 Volume(issue)/page/year: -,190,1963 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X7349 No. of Facilities: 7 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 103 (estimated) No. of Female Employees: 52 (estimated)
Risk Phrases R23/25
Safety Phrases 1-22-45
RIDADR UN 2811
17575-22-3 structure

17575-22-3

~%

17598-65-1 structure

17598-65-1

Literature: Helvetica Chimica Acta, , vol. 16, p. 1390,1407 Helvetica Chimica Acta, , vol. 17, p. 592,613
20830-75-5 structure

20830-75-5

572-09-8 structure

572-09-8

~%

17598-65-1 structure

17598-65-1

Literature: Advanced Synthesis and Catalysis, , vol. 355, # 13 p. 2518 - 2524
1469804-92-9 structure

1469804-92-9

~91%

17598-65-1 structure

17598-65-1

Literature: Muramatsu, Wataru; Yoshimatsu, Hirofumi Advanced Synthesis and Catalysis, 2013 , vol. 355, # 13 p. 2518 - 2524

Chemsrc provides CAS#:17598-65-1 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 17598-65-1 | Chemsrc address: https://m.chemsrc.com/en/baike/1032538.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved